BAVENCIO® (avelumab) is the FIRST and ONLY FDA-approved anti-PD-L1 immunotherapy for metastatic Merkel cell carcinoma (mMCC)1

BAVENCIO is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

NCCN

Avelumab (BAVENCIO)

RECOMMENDED by the National Comprehensive Cancer Network® (NCCN®) as an option for patients with disseminated Merkel cell carcinoma (category 2A*)2

*Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References: 1. U.S. National Library of Medicine. DailyMed: Advanced Search. Indication And Usage Section (34067-9). https://dailymed.nlm.nih.gov/dailymed/search.cfm? adv=1&labeltype=all&pagesize=200&page=1&query=34067-9%3A%28merkel+cell+carcinoma%29+. Accessed March 28, 2021. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Merkel Cell Carcinoma V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May 20, 2021. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.